KyungDong Pharm Co., Ltd. launches DPP-4 inhibitory diabetes treatment drug “Teneritin Tablet, TeneriM Sustained-release Tablet.”
“Teneritin, TeneriM extended-release tablets” are teneligliptin single drug and teneligliptin/metformin combination drug, and their main ingredient is teneligliptin, which inhibits DPP-4.
As a result of related clinical studies, teneligliptin achieved the target glycated hemoglobin of about 70%, showing a higher achievement rate than other DPP-4 inhibitors and showing excellent blood sugar strengthening effects.
It also has the advantage of being easy to prescribe for patients with renal impairment as it does not require dosage adjustment.
Unlike other companies, KyungDong Pharm seeks to ensure stability in supply and demand by directly producing and manufacturing the products and selling them exclusively.
In addition, the company plans to continue to expand its product pipeline for diabetes drugs by launching other DPP-4 inhibitors and SGLT-2 inhibitors in 2023.
♤Product Information♤
▶ Category: Prescription drugs
▶ Product name: Teneritin tablet 20mg, TeneriM extended-release tablet 10/500, 10/750, 20/1000mg
▶ Ingredient content: teneligliptin 20mg, teneligliptin/metformin 10/500, 10/750, 20/1000mg
▶ Efficacy: Administered as an adjunct to diet/exercise therapy to improve blood sugar control in adult type 2 diabetic patients.
▶ Dosage and usage
- Teneritin tablet 20mg: 1 tablet once a day
- Teneriem extended-release tablets: Take once a day with dinner (10/500, 10/750mg: 2 tablets at a time, 20/1000mg: 1 tablet at a time)
▶ Insurance drug price: Teneritin tablet 665 won, TeneriM extended-release tablet 334 won, 334 won, 665 won / tablet
▶ Packaging unit: 30 tablets/bottle
▶Remarks: Teneritin tablet release date 10/26, TeneriM extended-release tablet release date 11/1
※ Please refer to the product manual for other details such as precautions for use.